# Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma

> **NCT03827070** · PHASE1 · UNKNOWN · sponsor: **Center Trials & Treatment Europe** · enrollment: 12 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Afatinib
- **DRUG:** Talcum powder

## Key facts

- **NCT ID:** NCT03827070
- **Lead sponsor:** Center Trials & Treatment Europe
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-05
- **Primary completion:** 2023-02-21
- **Final completion:** 2023-07-21
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03827070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03827070, "Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03827070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*